JP2022520107A5 - - Google Patents
Info
- Publication number
- JP2022520107A5 JP2022520107A5 JP2021547420A JP2021547420A JP2022520107A5 JP 2022520107 A5 JP2022520107 A5 JP 2022520107A5 JP 2021547420 A JP2021547420 A JP 2021547420A JP 2021547420 A JP2021547420 A JP 2021547420A JP 2022520107 A5 JP2022520107 A5 JP 2022520107A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- use according
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025051765A JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805350P | 2019-02-14 | 2019-02-14 | |
| US62/805,350 | 2019-02-14 | ||
| US201962814935P | 2019-03-07 | 2019-03-07 | |
| US62/814,935 | 2019-03-07 | ||
| PCT/US2020/018113 WO2020168079A1 (en) | 2019-02-14 | 2020-02-13 | Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051765A Division JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520107A JP2022520107A (ja) | 2022-03-28 |
| JP2022520107A5 true JP2022520107A5 (enExample) | 2023-02-20 |
Family
ID=69954108
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547420A Withdrawn JP2022520107A (ja) | 2019-02-14 | 2020-02-13 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
| JP2025051765A Pending JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051765A Pending JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200331993A1 (enExample) |
| EP (1) | EP3924380A1 (enExample) |
| JP (2) | JP2022520107A (enExample) |
| KR (2) | KR20210126045A (enExample) |
| CN (2) | CN113614106A (enExample) |
| AU (1) | AU2020223298A1 (enExample) |
| CA (1) | CA3130300A1 (enExample) |
| MX (1) | MX2021009789A (enExample) |
| WO (1) | WO2020168079A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017269839A1 (en) | 2016-05-27 | 2018-11-22 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| US12620484B2 (en) | 2020-08-24 | 2026-05-05 | Nvidia Corporation | Machine-learning techniques for oxygen therapy prediction using medical imaging data and clinical metadata |
| EP4378479A3 (en) * | 2021-01-22 | 2024-09-25 | Alexion Pharmaceuticals, Inc. | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
| US20250154232A1 (en) * | 2021-07-14 | 2025-05-15 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US20160168237A1 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| SG10201710322VA (en) | 2014-12-19 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| AU2017269839A1 (en) * | 2016-05-27 | 2018-11-22 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| WO2017218515A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| BR112020001703B1 (pt) * | 2017-07-27 | 2024-01-02 | Alexion Pharmaceuticals, Inc | Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma |
| EP3700928A1 (en) * | 2017-10-26 | 2020-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
-
2020
- 2020-02-13 CN CN202080021230.XA patent/CN113614106A/zh active Pending
- 2020-02-13 AU AU2020223298A patent/AU2020223298A1/en active Pending
- 2020-02-13 JP JP2021547420A patent/JP2022520107A/ja not_active Withdrawn
- 2020-02-13 WO PCT/US2020/018113 patent/WO2020168079A1/en not_active Ceased
- 2020-02-13 KR KR1020217028172A patent/KR20210126045A/ko not_active Ceased
- 2020-02-13 CA CA3130300A patent/CA3130300A1/en active Pending
- 2020-02-13 CN CN202411307488.2A patent/CN119326881A/zh active Pending
- 2020-02-13 EP EP20713785.2A patent/EP3924380A1/en active Pending
- 2020-02-13 MX MX2021009789A patent/MX2021009789A/es unknown
- 2020-02-13 KR KR1020267008814A patent/KR20260046520A/ko active Pending
- 2020-02-14 US US16/791,415 patent/US20200331993A1/en not_active Abandoned
-
2024
- 2024-10-31 US US18/933,215 patent/US20250243264A1/en active Pending
-
2025
- 2025-03-26 JP JP2025051765A patent/JP2025092553A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11453716B2 (en) | Single domain serum albumin binding protein | |
| JP2021526534A5 (enExample) | ||
| JP2018535948A5 (enExample) | ||
| RU2015114923A (ru) | СПОСОБЫ ЛЕЧЕНИЯ IL-1β-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ | |
| JP2020536097A5 (enExample) | ||
| US10954292B2 (en) | Anti-PACAP antibody | |
| JP2021525718A5 (enExample) | ||
| CN111108117A (zh) | 胰高血糖素样肽1受体激动剂及其用途 | |
| RU2019106804A (ru) | Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4 | |
| JP2020521745A (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| CN111886252A (zh) | 促进胰岛细胞生长的方法 | |
| JP2019519584A5 (enExample) | ||
| US20120308564A1 (en) | Treatment of a metabolic disorder | |
| JP2023537078A5 (enExample) | ||
| JP2023542879A5 (enExample) | ||
| JP2018533588A (ja) | 治療パラダイム | |
| JP2023506779A5 (enExample) | ||
| JP2024526742A5 (enExample) | ||
| AU2020315367A1 (en) | Metallothionein antibodies and their use | |
| JP7217287B2 (ja) | アミロイド症の処置および予防 | |
| TWI825687B (zh) | 抗ｃｘｃｒ２抗體及其用途 | |
| US20250270274A1 (en) | Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity | |
| US20240043545A1 (en) | Methods and compositions for treatment of thyroid eye disease | |
| EA044759B1 (ru) | Лечение и профилактика амилоидоза |